Voltar
Artigo Produção Nacional Revisado por pares
BIBTEX RIS

Alterations to antigen-specific immune responses before and after multidrug therapy of leprosy

2015; Elsevier BV; Volume: 83; Issue: 2 Linguagem: Inglês

10.1016/j.diagmicrobio.2015.06.021

ISSN

1879-0070

Autores

Aline Araújo Freitas, Regiane Morillas Oliveira, Emerith Mayra Hungria, Ludimila Paula Vaz Cardoso, Ana Lúcia Osório Maroccolo de Sousa, Maurício Barcelos Costa, Steven G. Reed, Malcolm S. Duthie, Mariane M. A. Stefani,

Tópico(s)

Infectious Diseases and Tuberculosis

Resumo

This study evaluated the impact of leprosy multidrug therapy (MDT) on cell-mediated immunity (CMI) and antibody responses at diagnosis in untreated paucibacillary (PB) (n=15) and multibacillary (MB) patients (n=15) using a panel of Mycobacterium leprae recombinant antigens (rMLs) (CMI: 46f, ML0276, ML2055, leprosy IDRI diagnostic 1 [LID-1], and ML2629, as negative control; serology: LID-1, 46f, 92f, and 33f, as negative control, and phenolic glycolipid I [PGL-I]) and at 2 time points after MDT (PB: 8-20months; MB: 4-22months). At diagnosis, PB patients produced interferon gamma (IFNγ), and MB patients exhibited low/absent response. Shortly after MDT, IFNγ production in PB patients declined except for LID-1; MB patients produced IFNγ to LID-1. Almost 2years after MDT, IFNγ levels declined in PB and MB patients. Most untreated PB patients were seronegative to PGL-I and rML, remaining so after MDT. Most untreated MB patients were seropositive to all antigens, and IgG to rMLs declined after MDT. Reduction in antigen-specific CMI in PB and in antibody response in MB patients may help monitor MDT effectiveness.

Referência(s)